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Evgeny N Imyanitov1,2,3* and Tomasz Byrski4,5Abstract: The history of specific therapy for hereditary tumors dates back to mid 1980s and involves a number of
reports demonstrating regression of familial colon polyps upon administration of sulindac. Virtually no clinical
studies on other hereditary cancer types were available until the year 2009, when Byrski et al. presented the data
on unprecedented sensitivity of BRCA1-associated breast malignancies to cisplatin. This breakthrough has revived
interest to the treatment of cancer in germ-line mutation carriers. Recent trials and clinical observations have
confirmed the efficacy of platinating agents and PARP inhibitors in BRCA1/2-driven breast, ovarian and pancreatic
carcinomas. Pegylated liposomal doxorubicin may be considered as a promising treatment option for BRCA1/2-
related ovarian cancer after the failure of platinum-containing therapy. Several novel drugs have been recently
introduced in the management of rare familial tumor syndromes. Vandetanib, a low-molecular weight RET kinase
inhibitor, demonstrated substantial efficacy in the treatment of hereditary and sporadic medullary thyroid cancer.
Vismodegib, an inhibitor of SMO oncoprotein, caused regression of basal-cell carcinomas in patients with Gorlin
syndrome. Down-regulation of mTOR kinase by everolimus has been successfully used for the therapy of
subependymal giant-cell astrocytomas in patients with tuberous sclerosis. The achievements in the prevention,
diagnostics and treatment of hereditary cancers may serve as an excellent example of triumph of translational
medicine.Introduction
1-5% of human cancers develop due to known germ-line
defects. Virtually all major hereditary tumor types differ
from their sporadic counterparts with respect to the
underlying biological mechanisms, and thus may be con-
sidered as a somewhat distinct disease entity. First reports
on specific therapy of familial tumors date back to mid
1980s [1]. It is getting increasingly apparent that cancers
arising in mutation carriers often demonstrate peculiar
spectrum of drug sensitivity [2]. Here we review recent ad-
vances and controversies in this field.
Breast cancer
There are over 10 genes causing hereditary forms of breast
cancer (BC), however only BRCA1- and BRCA2-related
disease has been studied with sufficient level of comprehen-
sion. It is commonly stated that BRCA-driven malignancies
are triggered by somatic inactivation of the remaining* Correspondence: evgeny@imyanitov.spb.ru
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distribution, and reproduction in any medium(wild-type) BRCA allele, thus providing an unique oppor-
tunity for a tumor-specific therapy. Indeed, while normal
tissues of BRCA mutation carriers retain a non-altered
copy of the gene, the transformed cells are characterized by
complete loss of BRCA function. Absence of the BRCA1 or
BRCA2 compromises DNA repair and increases sensitivity
of the cell to particular DNA damaging agents [2,3].
Clinical studies on breast cancer demonstrated an unique
sensitivity of BRCA1-accociated tumors to cisplatin [4].
The available literature describes 15 BRCA1 carriers
treated by neoadjuvant cisplatin for BC, and 13 (87%) of
them showed pathological complete response (pCR) [5-8].
First data on the use of cisplatin in metastatic setting have
been published recently. Byrski et al. [9] observed objective
responses in 16/20 (80%) patients, some of them heavily
pretreated. Moiseyenko et al. [10] described a patient
with BRCA1-related BC whose tumor did not respond to
the first-line anthracyline-taxane therapy, but markedly
regressed after administration of cisplatin. An experimental
PARP1 inhibitor, olaparib, has also shown very encouraging
results in both BRCA1- and BRCA2-driven BC, however
its regulatory approval may take longer than initially
expected [11].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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apoptosis, therefore BRCA1-deficiency may mediate re-
sistance to docetaxel or paclitaxel. Two systematic studies
on BC provided strong support to this hypothesis. Kriege
et al. [12] investigated taxane monotherapy for the treat-
ment of metastatic BC disease, and described lower
response rate and shorter progression-free survival in
BRCA1-heterozygous patients as compared to BRCA2-
related and sporadic cases. Byrski et al. [6] reported
only 2/25 (8%) pathological complete responses in the
BRCA1 patients treated by anthracycline-taxane (AT)
combinations, while presumably less potent taxane-free
anthracycline-containing regimens yielded 22% (11/51)
pCRs. However, Arun et al. [13] recently presented the
experience of neoadjuvant BC treatment in the MD
Anderson Cancer Center, where BRCA1 carriers dem-
onstrated high pCR rates for anthracycline-containing
regimens both with and without taxanes (21/46 (46%)
and 4/9 (44%), respectively). Entirely different outcomes
of the AT therapy in the studies of Byrski et al. [6] and Arun
et al. [13] deserve particular attention. It is essential to co-
mment that while Byrski et al. [6] used the combination of
doxorubicin and docetaxel for all described patients, run
et al. [13] utilized a number of AT regimens; for example,
some patients received distinct anthracycline (epirubicin)
and/or taxane (paclitaxel) and/or were treated with the
addition of 5-fluorouracil and/or cyclophosphamide.
A number of issues may be considered while designing
the BC studies for the near future. The list of known BC
genes is rapidly expanding, with the CHEK2 being appa-
rently the most frequent cause of hereditary BC after
BRCA1 and BRCA2. Drug response of CHEK2-related
BCs has not been evaluated yet, neither in laboratory ex-
periments nor in the patients [2]. Furthermore, the whole
idea of selective chemosensitivity of BRCA-related BC is
based on the “two-hit” hypothesis; however, some of the
recent data indicate, that BCs arising in BRCA1 mutation
carriers do not necessarily display the loss of the remaining
allele, and haploinsufficiency of heterozygous BRCA1 cells
may at least in some instances contribute to tumorigenesis
[14-16]. It is of interest whether the actual somatic status
of BRCA genes indeed influences the tumor response
to the treatment. Most importantly, even highly BRCA-
selective drugs, like cisplatin or PARP1 inhibitors, offer
only a temporary tumor regression in the metastatic BC
patients. It is hoped that intelligent combining of BRCA-
specific compounds may offer significantly better outcomes
[17]. The reported instances of cure of BRCA-mutated
stage IV BCs by high-dose chemotherapy may deserve par-
ticular attention in this respect [18,19].
Ovarian cancer
Approximately 15% of ovarian cancers (OCs) arise due
to inherited BRCA1 or BRCA2 mutation. In addition, asignificant portion of serous OCs demonstrate somatic
inactivation of BRCA1/2 genes and therefore have simi-
lar biological properties [20]. BRCA deficiency explains
sensitivity of OC to platinum-containing therapy and
PARP1 inhibitors, which appears to be somewhat more
pronounced in hereditary versus sporadic cases [21-23].
Prolonged drug treatment usually leads to the tumor re-
sistance, which at least in some instances is attributed to
the restoration of the BRCA gene function through the
gain of second mutation [24].
The most noticeable achievement of the recent months
is a convincing demonstration of high efficacy of pegylated
liposomal doxorubicin (PLD) in BRCA-related ovarian
cancer. PLD is an advanced formulation of doxorubicin,
which is characterized by more favorable pharmacoki-
netic, pharmacodynamic and safety profiles as compared
to conventional anthracyclines. PLD is included in the
spectrum of drugs, which may be used for the treatment
of ovarian cancer after failure of platinum-based therapy.
Safra et al. [25] retrospectively compared the performance
of 2nd- and 3rd-line PLD in proven BRCA1/2-carriers
versus presumably non-hereditary OC patients; the object-
ive response rates were 68% versus 49%, and the median
time to treatment failure was 15.8 months versus 8.1 -
months. Adams et al. [26] considered PLD users with an
average 2.7 prior chemotherapeutic regimens (range: 0-6),
and also observed increased frequency of tumor responses
(57% versus 20%) and prolonged progression-free survival
(27.1 weeks versus 17.0 weeks) in BRCA mutation carriers.
Kaye et al. [27] performed randomized comparison of PLD
and olaparib in heavily pretreated BRCA-heterozygous OC
patients; PLD arm demonstrated objective response rate of
18% and progression survival of 7.1 months, that was simi-
lar to the efficacy of the PARP1 inhibition. In contrast to
PLD, topotecan, being also a standard therapeutic option
for the previously treated ovarian cancer, showed null cli-
nical benefit rate in BRCA mutation carriers [28].
A high-throughput pharmaceutical screen on BRCA2-
deficient mouse mammary tumor cells pointed at poten-
tial efficacy of a well-known alkylating cytotoxic drug,
melphalan [29]. In accordance with laboratory findings,
Osher et al. [30] reported a patient with metastatic ova-
rian cancer, who received melphalan during 1 year in
1980s and remains disease-free for over 25 years.
Pancreatic cancer
Pancreatic cancer (PC) is known for its resistance to vir-
tually all available cytotoxic agents. However, 5% to 10%
of PCs are caused by germ-line mutations in BRCA1,
BRCA2 or PALB2 genes, and this subset of tumors may
demonstrate significant sensitivity to DNA damaging
agents and PARP1 inhibitors. There is a number of case
observations supporting this assumption [31-33]. Two
systematic studies on this issue have been reported in
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with advanced BRCA-related PC receiving PARP inhibi-
tor alone or in combination with chemotherapy; 3 tu-
mors responded to the treatment and 1 demonstrated
stabilization of the disease. 6 patients from the same
study underwent platinum-containing first-line therapy,
and 5 of them showed response to the treatment. Faluyi
et al. [35] described 11 BRCA-driven cases of metastatic
PC; 2 complete and 3 partial responses were docu-
mented in 5 patients receiving platinum-containing drug
combinations, while only 1 out of 6 PCs responded to
gemcitabine.
Colorectal cancer
Almost all colorectal cancers (CRCs), which arise in car-
riers of DNA mismatch repair (MMR) gene mutations,
show instability of microsatellite repeats (MSI). MSI is
also characteristic for a subset of sporadic CRCs. Both
hereditary and sporadic MSI+ CRCs demonstrate rea-
sonably favorable prognosis, probably due to immuno-
genicity of microsatellite unstable tumors. While familial
CRCs are usually early-onset, sporadic MSI+ tumors are
typical for elderly individuals. The latter category of MSI
+ cancers is also characterized by the presence of BRAF
mutations [36]. MSI test is technically easier that the de-
tection of germ-line defects in MMR genes, therefore
virtually all available studies consider MSI status without
referring to inherited mutations in the MLH1, MSH2 or
other candidates. Recently Sinicrope et al. [37] attempted
to discriminate hereditary versus sporadic MSI+ CRCs
based on patients age (younger versus older than 55 years)
and, wherever possible, somatic BRAF status. This analysis
led to suggestion that presumably hereditary stage III
MSI+ CRCs do benefit from 5-fluorouracil-based therapy,
while presumably sporadic ones do not.
There is an emerging class of targeted drugs, whose ac-
tion is based on stimulation of local antitumor immune
response [38,39]. They deserve to be considered for the
future trials on MSI+ colorectal carcinomas, given a pro-
nounced immunogenicity of this CRC subset.
Medullary thyroid cancer
Hereditary forms of medullary thyroid cancer (MTC)
develop due to inherited mutation in the RET oncogene
and demonstrate pronounced sensitivity to the RET
tyrosine kinase inhibitor, vandetanib [40]. Vandetanib
studies were recently expanded to non-selected MTC,
given frequent somatic RET alterations in sporadic tu-
mors of this type [41]. The progression-free survival rate
at 6 months was 83% for vandetanib versus 63% for
placebo. Most of included patients had either confirmed
RET mutation (hereditary or sporadic) or unknown
RET status, and the former tended to fare better than
the latter. This study led to the approval of the drug;interestingly, the European Medicines Agency recom-
mends to evaluate RET mutation status while considering
vandetanib therapy [http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/
002315/WC500123555.pdf], while the Food and Drug
Administration states in the drug label that there is no
evidence of a relationship between RET mutations and
efficacy of this compound [http://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/022405s001lbl.pdf].Basal-cell nevus syndrome
Basal-cell nevus (Gorlin) syndrome is a rare hereditary
disorder which is caused by mutation in the PTCH1 gene.
PTCH1 inactivation abolishes its negative regulation of
the SMO oncogene and thus initiates the growth of mul-
tiple basal-cell carcinomas. Clinical administration of a
specific SMO inhibitor, vismodegib, prevented the appear-
ance of new malignancies and resulted in the regression of
existing neoplasms. None of the lesions progressed during
the treatment, however the systemic tumor disease quickly
relapsed after discontinuation of the therapy [42].Astrocytomas in tuberous sclerosis
Tuberous sclerosis is caused by germ-line mutations in
TSC1 or TSC2 suppressor genes. Disruption of TSC1 or
TSC2 leads to uncontrolled activation of mTOR kinase,
and, consequently, to neoplastic growth. Tumors arising
in patients with tuberous sclerosis are usually benign,
however some of the neoplasms, especially if located in
the brain, may cause severe disability and death. Recent
development of specific mTOR inhibitors provided novel
opportunities for the management of tuberous sclerosis.
In particular, promising results have been achieved with
everolimus: administration of this drug to the patients
with serial subependymal giant-cell astrocytomas led to
the marked tumor reduction in 21 (75%) of 28 enrolled
patients [43].Conclusions and perspectives
Recent studies have convincingly demonstrated that he-
reditary and sporadic tumors may indeed require distinct
treatment approaches. Ongoing revolution in technolo-
gies of DNA analysis, particularly the invention of next-
generation sequencing, allows to expect that dozens of
new familial cancer genes will be identified in the near
future. Furthermore, dramatic increase of velocity and
cost-efficiency of germ-line mutation testing provides
the hope that virtually every cancer patient will soon be
undergoing genetic examination right at the time of
tumor diagnosis [44]. Advances in the management of
hereditary cancer syndromes may serve as an excellent
example of the power of translational medicine.
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